MannKind falls after licensing inhaled GLP-1 program with Rose Pharma
MannKind shares traded lower after the company entered a licensing and collaboration agreement with Rose Pharma to develop an inhaled, rapid-acting GLP-1 receptor agonist using Technosphere technology.